IN8BIO
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies... , which are designed to effectively identify and eradicate tumor cells. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
IN8BIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.in8bio.com
Total Employee:
1+
Status:
Active
Total Funding:
45.73 M USD
Technology used in webpage:
SPF Google Apps For Business Google Google Cloud Google DNS Google Domains Google Cloud DNS Google Cloud South Carolina
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bios Partners
Bios Partners investment in Series A - IN8Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-09 | IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer |
| 2021-11-16 | IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.in8bio.com Semrush global rank: 1.44 M Semrush visits lastest month: 19.31 K
- Host name: 113.47.227.35.bc.googleusercontent.com
- IP address: 35.227.47.113
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
